Venture Capital Access Online | The eMarketplace for the Venture Capital Industry

 

Bookmark and Share   

Home

Marketplace
Database
Deals
News
Store
Resources
Contact Us

 

 

 

News

VCPro Database 2014 (17th Edition) Now Available! Newly released


Venture Capital Deals Spreadsheet Now Available Newly released


 

Tolero Pharmaceuticals Closes $14.2 Million Series B Financing

-- New Funding will Support Continued Development of Alvocidib and the Advancement of Promising Pipeline Assets --

SALT LAKE CITY, August 7, 2014-- Tolero Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing treatments for oncology and hematologic diseases, today announced the closing of a $14.2 million Series B financing, led by funds advised by Fred Alger Management Inc. and other institutional and individual investors.

Proceeds will support the further development and commercialization of Tolero’s lead program, alvocidib, being developed for the treatment of acute myeloid leukemia (AML), and the ongoing advancement of the Company’s preclinical pipeline. Tolero plans to initiate a Phase 3 clinical trial of alvocidib in patients with AML in 2015.

“This financing enables Tolero to continue the clinical and regulatory advancement of alvocidib, and positions us well to further develop our exciting pipeline of novel molecules in clinical development,” said Dr. David Bearss, co-founder and CEO of Tolero Pharmaceuticals. “Our new and returning investors have provided a resounding endorsement of our approach to discovering and developing important new medicines for patients with cancer and other serious diseases.”

T.R. Winston & Company, LLC acted as exclusive placement agent to Tolero.

About Alvocidib

Alvocidib is a potent small molecule inhibitor of cyclin-dependent kinases (CDKs) in development as a front-line combination therapy for acute myeloid leukemia (AML) and relapsed/refractory AML. CDKs are regulatory proteins that are critical to cellular replication and regulation of gene expression. Given the key role CDK de-regulation plays in unchecked cell division and growth, CDKs remain an attractive target for the treatment of various cancers.

About Tolero

Tolero Pharmaceuticals is a clinical stage biopharmaceutical company developing treatments to improve and extend the lives of patients with serious oncological and hematological diseases. Our diverse pipeline targets important biological drivers of blood disorders to treat leukemias and anemia as well as important targets of drug resistance and transcriptional control. For more information, visit www.toleropharma.com.

Contact:
Tolero Pharmaceuticals, Inc.
Joe Nilson, 801-285-6003
bizdev@toleropharma.com


News Index

Venture Capital Database

Venture Capital Deals Spreadsheet

 

 NEWS

Latest VC News
VC News Archive
News Search
Venture Capital Deals
RSS News Feed

List Your Firm

Entrepreneurs
Investors
Advisors

Venture Capital Database

VCPro Database
Download Trial
Buy Now

Venture Capital Deals

vcaDeals
Download Sample
Buy Now

VC Tools

VC Pitch
Private Placement Memorandum

Business Plan Tools

Free Business Plan Template
Business Plan Tools

 

 

Copyright © 1998-2014 Access InterComm  All rights reserved. 
Site Map | Privacy Statement | Legal Notice & Disclaimer